Ashland Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a ASH research report →
Range $75 – $85
Price Chart
About the company
Ashland Inc. operates as a global supplier of specialized chemicals and additives. Its business activities are structured into four main divisions: Life Sciences; Personal Care & Household; Specialty Additives; and Intermediates and Solvents.
- CEO
- Guillermo Novo
- IPO
- 1980
- Employees
- 2,800
- HQ
- Wilmington, DE, US
Get TickerSpark's AI analysis on ASH
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $3.32B
- P/E
- 848.89
- Fwd P/E
- 17.13
- PEG
- -10.46
- P/S
- 1.88
- P/B
- 1.90
- EV/EBITDA
- 13.82
- Div Yield
- 2.19%
- Gross Margin
- 30.11%
- Op Margin
- 5.53%
- Net Margin
- 0.21%
- ROE
- 0.21%
- ROIC
- 0.90%
Latest fiscal year · YoY change
- Revenue
- $1.86B+2.1%
- Gross Profit
- $601.00M+9.5%
- Op Income
- $105.00M
- Net Income
- $4.00M+100.5%
- EPS
- $0.09+100.5%
- OCF Growth
- +260.6%
- FCF Growth
- +6375.0%
- 52W High
- $79.50
- 52W Low
- $48.19
- 50D MA
- $72.12
- 200D MA
- $64.66
- Beta
- 0.36
- RSI (14)
- 49
- Avg Volume
- 652.39K
Earnings call summaries
Pick a quarter — each call distilled into takeaways, results, and a bull vs bear read.
Ashland reported a solid fiscal fourth quarter with 4% sales growth, higher EBITDA, strong cash generation, and upbeat fiscal 2027 guidance despite Hopewell-related profitability drag and some market softness.· November 4, 2026
- Q4 sales rose 4% to $498 million and adjusted EBITDA rose 2% to $121 million.
- Life Sciences and Personal Care were standouts, with record 35.6% Life Sciences EBITDA margin and 30.1% Personal Care margin.
- Specialty Additives growth was strong in Coatings and Performance Specialties, but profit was pressured by lower Hopewell productivity.
- Full-year 2027 guidance calls for $1.905 billion-$1.975 billion in sales and $405 million-$435 million in adjusted EBITDA.
- Management said execute, globalize, and innovate are now translating into commercial gains, while the main fix remains improving Hopewell output and manufacturing productivity.
Fourth quarter sales were $498 million, up 4% year over year. Adjusted EBITDA was $121 million, up 2%, adjusted operating income was $77 million versus $71 million, and adjusted income from continuing operations excluding intangible amortization was $52 million, or $1.12 per diluted share, versus $50 million, or $1.08 per diluted share. Cash flow from operating activities was $90 million versus $40 million, and ongoing free cash flow was $74 million versus $52 million, equal to 61% of adjusted EBITDA conversion versus 44% a year ago. For fiscal 2027, Ashland expects sales of $1.905 billion-$1.975 billion, adjusted EBITDA of $405 million-$435 million, ongoing free cash flow conversion greater than 40% of adjusted EBITDA, and capital expenditures of up to about $140 million. Management also said it expects a stronger U.S. dollar to create about $20 million-$25 million of sales headwind and $7 million-$10 million of adjusted EBITDA headwind.
Guillermo Novo framed fiscal 2026 as proof that Ashland’s portfolio transformation is working, emphasizing strong commercial momentum in Life Sciences, Personal Care, Coatings, and Performance Specialties. He repeatedly pointed to execute, globalize, and innovate as the main growth engines, and said the company has now completed its transformation and is shifting to execution. His tone was constructive and confident, but he was clear that improving Hopewell productivity and converting commercial progress into higher consolidated profitability remain key priorities.
William Whitaker highlighted the quarter’s financial improvement: sales of $498 million, adjusted EBITDA of $121 million, operating cash flow of $90 million, and ongoing free cash flow of $74 million. He noted $480 million of cash, $976 million of total liquidity, and net leverage of 2.3x at year-end. For 2027, he said free cash flow conversion should be greater than 40% because of a planned modest inventory build and up to $140 million of capex, while also noting that over time Ashland still expects greater than 50% free cash flow conversion. He also quantified Hopewell’s impact as about $17.5 million of under-absorption for the year, with about $5 million carrying into Q1, and said the site should ramp toward about 25% higher output over the next phase.
Analysts focused on the durability of Personal Care and Life Sciences growth, the sustainability of margin gains, and whether the 2027 free cash flow guide implies a lower normalized rate. Management said Personal Care growth was mostly volume-driven and broad-based, with roughly 7% of the 8% growth from volumes, and said Life Sciences margin improvement came from strong pharma volumes, favorable mix, and pipeline-driven growth. Questions also centered on the CapEx increase and Hopewell; management said the capex step-up is mainly timing, to move debottlenecking forward and preserve flexibility, while Hopewell’s issues are operational rather than demand-related. On customer inventory risk, management said it does not see a 2022-style destocking dynamic in pharma or additives today.
The bull case from the call is that Ashland’s higher-value businesses are growing strongly and profitably: Life Sciences sales rose 4% with a 35.6% EBITDA margin, and Personal Care sales rose 8% with a 30.1% margin. Management said globalize and innovate beat their 2026 target by nearly 50%, pricing covered inflation, cash generation was strong, and 2027 guidance still implies growth despite FX headwinds and a measured macro view.
The main bear case is that Specialty Additives profitability is still constrained by Hopewell productivity, and management acknowledged about $17.5 million of under-absorption this year with some carryover into Q1. The company also flagged soft end markets in construction and energy/resources, planned maintenance in Cellulosics, a stronger U.S. dollar headwind, and a capex increase that may temper near-term free cash flow conversion below its longer-term level.
AI summary of the company's earnings call · Paraphrased · Not investment advice
- Free Float
- 81.7%
- Shares Outstanding
- 45.79M
- Float Shares
- 37.41M
of shares held by institutions
370 13F filers
Buy/sell ratio 0.53. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Blackrock, Inc. | 5.78M | ▲ 72.19K |
| Vanguard Group Inc | 4.54M | ▼ 70.99K |
| Standard Investments LLC | 4.53M | ▲ 1.90M |
| Dimensional Fund Advisors LP | 2.63M | ▲ 141.81K |
| Franklin Templeton Inc | 2.55M | ▼ 1.07M |
| Vanguard Portfolio Management LLC | 2.29M | ▼ 168.29K |
| Frontier Capital Management Co LLC | 2.00M | ▲ 87.22K |
| Ancora Advisors LLC | 1.95M | ▲ 1.95M |
| State Street Corp | 1.92M | ▲ 30.19K |
| Vanguard Capital Management LLC | 1.90M | ▼ 162.76K |
| Cooperman Leon G | 1.90M | ▲ 195.00K |
| Aqr Capital Management LLC | 1.82M | ▼ 188.17K |
Held by 400 ETFs
Biggest fund positions in ASH by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Nov 16, 26 | RICHARDSON SAMUEL | other | 235 |
| Nov 16, 26 | RICHARDSON SAMUEL | other | 69 |
| Nov 16, 26 | RICHARDSON SAMUEL | other | 235 |
| Nov 16, 26 | LAMPKIN ROBIN E. | other | 1,310 |
| Nov 16, 26 | LAMPKIN ROBIN E. | other | 382 |
| Nov 16, 26 | LAMPKIN ROBIN E. | other | 1,310 |
| Nov 16, 26 | MINICUCCI JAMES P. | other | 1,259 |
| Nov 16, 26 | MINICUCCI JAMES P. | other | 395 |
| Nov 16, 26 | MINICUCCI JAMES P. | other | 1,259 |
| Nov 16, 26 | WHITAKER WILLIAM | other | 367 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our ASH coverage
Recent articles, reports, and earnings notes.
Want a deeper read on ASH?
Generate a full analyst-grade report — bull/bear case, price targets, valuation depth, and a complete financial breakdown.
Regeneron Highlights New Data Across Malignant and Classical Hematology Programs at American Society of Hematology (ASH)
globenewswire.com · Nov 19
Bristol Myers Squibb Demonstrates Breadth and Clinical Momentum Across Blood Cancers and Rare Hematologic Disorders at ASH 2026
businesswire.com · Nov 19
Adaptive Biotechnologies Highlights clonoSEQ's Central Role in Advancing MRD-Guided Care Across Hematology at ASH 2026
globenewswire.com · Nov 18
Reviewing Perimeter Solutions (NYSE:PRM) & Ashland (NYSE:ASH)
defenseworld.net · Nov 17
Estrella Immunopharma Highlights ARTEMIS® T-Cell Therapy Data Selected for ASH 2026, Demonstrating Deep and Durable Leukemia Responses and Superior Extramedullary Disease Clearance Versus Conventional
gurufocus.com · Nov 16
Estrella Immunopharma Highlights ARTEMIS® T-Cell Therapy Data Selected for ASH 2026, Demonstrating Deep and Durable Leukemia Responses and Superior Extramedullary Disease Clearance Versus Conventional CAR-T in Preclinical Models
businesswire.com · Nov 16
Ashland: Focus On FY 2027 Financial Improvement And Potential Sale
seekingalpha.com · Nov 13
Ashland board authorizes quarterly dividend
globenewswire.com · Nov 11
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.
